About Proteinase-activated receptor 2
Proteinase-activated receptor 2 (F2RL1) is a protein
from Homo sapiens identified by UniProt accession
P55085, 397 residues long.
MolForge cross-references it against 0 known binders and
365 disease associations.
Target properties
| Protein name | Proteinase-activated receptor 2 |
| UniProt accession | P55085 |
| Gene | F2RL1 |
| Organism | Homo sapiens |
| Length | 397 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (365)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.46
- calcium measurement · score 0.39
- mean platelet volume · score 0.36
- serum albumin measurement · score 0.29
- serum gamma-glutamyl transferase measurement · score 0.29
- glioblastoma multiforme · score 0.27
- proteinase-activated receptor 1 measurement · score 0.23
- monocyte count · score 0.20
- head and neck squamous cell carcinoma · score 0.16
- medulloblastoma · score 0.13
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P55085-F1 | alphafold | PREDICTED | 82.08 | — |
Amino-acid sequence (397 residues)
MRSPSAAWLL GAAILLAASL SCSGTIQGTN RSSKGRSLIG KVDGTSHVTG KGVTVETVFS VDEFSASVLT GKLTTVFLPI VYTIVFVVGL PSNGMALWVF LFRTKKKHPA VIYMANLALA DLLSVIWFPL KIAYHIHGNN WIYGEALCNV LIGFFYGNMY CSILFMTCLS VQRYWVIVNP MGHSRKKANI AIGISLAIWL LILLVTIPLY VVKQTIFIPA LNITTCHDVL PEQLLVGDMF NYFLSLAIGV FLFPAFLTAS AYVLMIRMLR SSAMDENSEK KRKRAIKLIV TVLAMYLICF TPSNLLLVVH YFLIKSQGQS HVYALYIVAL CLSTLNSCID PFVYYFVSHD FRDHAKNALL CRSVRTVKQM QVSLTSKKHS RKSSSYSSSS TTVKTSY
Explore Proteinase-activated receptor 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets